Le Projet « CTIONCOTEST™ » est bénéficiaire du dispositif Aide au Développement Deeptech
Durée : 36 mois
Budget total du projet : 3 000 000 €
Aides perçues : 1 250 000 €
Le projet
The objective of CTIONCOTEST™ is to develop an automated process for 3D-bioprinting human microtumors to improve the reliability of preclinical drug testing and replace animal testing. By creating models that closely reflect a patient’s own tumor environment and maintain viability for over 100 days, the project seeks to reduce high drug failure rates. This provides a practical, 100% human-derived alternative to animal testing to better support personalized cancer research. These highly predictive platforms mimic real patient biology, allowing for long-term study of drug resistance in high-mortality cancers. Designed to de-risk pharmaceutical development and accelerate life-saving treatments, this industrial-scale solution will hit the market in 2029.
À propos de CTIBIOTECH™
Based in Lyon and founded in 2009, CTIBIOTECH™ is an innovative French CRDMO specializing in advanced 3D bioprinting and human tissue engineering. As a leader in regenerative medicine, its core expertise lies in developing highly predictive, 100% human-derived preclinical models. The structure provides the pharmaceutical industry with automated, industrial-scale tools to replace animal testing and accelerate the development of life-saving cancer drugs.
Les partenaires
Centre Léon Bérard: A leading cancer center providing clinical expertise and access to patient primary tumor cells for high-fidelity 3D model development.
Hospices Civils de Lyon (HCL): France’s second-largest university hospital, providing critical clinical validation and biological samples for the project.
Transgene: A biotech partner specializing in immunotherapy, focused on testing the efficacy of viral-based cancer treatments on the 3D bioprinted models.
Oncodesign Services: A leading CRO providing expertise in preclinical pharmacology to evaluate drug response and resistance within the bioprinted microtumors.
Novotec: A specialist in histology and tissue characterization, responsible for analyzing the biological structure and cellular viability of the models.
Medical University Plovdiv: An academic partner contributing international research expertise to enhance the biological complexity of the tumor environments.
GenXMap: A technical partner providing advanced genomic analysis to ensure the genetic consistency between patient tumors and bioprinted replicas.
L’accompagnement de Lyonbiopôle
Lyonbiopôle accompagne et conseille ses membres à chaque étape dans leur démarche afin de maximiser leurs chances de succès
« As a certified member of the Lyonbiopôle Auvergne-Rhône-Alpes cluster, the project benefited from its « labelization, » which provided critical strategic support. This endorsement facilitated high-level networking within a world-class ecosystem, connecting the project with key academic, clinical, and industrial partners. This collaborative framework was essential for securing the Bpifrance funding and refining the project’s market entry strategy. ».
Clément MILET | Laboratory & Quality Director | CTIBIOTECH™
